

PIVOTALboost trial recruitment completed

Dear PIVOTALboost trial participant, we wanted to take this opportunity to update you on the progress of the trial and extend our thanks for your participation. PIVOTALboost is a research study designed to find out if there is a benefit of treating the pelvic lymph nodes in addition to treating the prostate gland. It also aims to find out if there is any benefit in treating the prostate gland with high radiation dose (boost radiotherapy).

The trial opened in Jan 2018 and enrolled the last patient in August 2024, having successfully recruited all the participants needed. You are one of the 2232 people that entered the study, which took place in 49 hospitals across the UK

What happens next?

The trial will continue to follow up participants as set out in the information given to you when you joined the trial. We therefore ask you to continue to attend the follow up appointments as scheduled and complete any quality of life questionnaires you receive. We have excellent rates of response for the quality of life questionnaires, which is very important for the results of the trial, and would like to thank all participants who continue to complete and return them.



When will the trial results be available?



Independent experts will review the progress of the research and the results will be published in a medical journal and on the CRUK website as soon as there is enough information to be sure the results are reliable. The results of this study are not likely to be available for at least another 5 years. The results will help to decide how to treat prostate cancer in the future.

If, at any time, you have any questions about the study you should contact your hospital team.

PIVOTALboost is sponsored by the Institute of Cancer Research. This research is being conducted in the UK with a grant from Cancer Research UK (CRUK/16/018). PIVOTALboost is a NIHR CRN Portfolio trial.

